IAI Announces Medical Assist ELECYLINDER Series

February 1, 2021

ELECYLINDER, IAI

IAI (Intelligent Actuator Incorporated), a leading robotics provider headquartered in Shizuoka, Japan,­­ would like to introduce their ELECYLINDER®  Series.

Introducing the ELECYLINDER electric actuator developed by IAI. The main features are easy operation, AVD (acceleration / speed / deceleration) that can be adjusted individually, and high performance. Due to its stable quality, it is ideal for the manufacturing industry of medical products where product accuracy is required.

Here is an example of how an ELECYLINDER Series was used to improve a face mask manufacturing process. While using a conventional air cylinder to cut mask connection parts, stoppers gradually worn down. This caused cutting positions to shift, which led to defective products and production had to stop. Implementing the ELECYLINDER eliminated damaged stopper parts, production continued, and productivity got a boost.

“IAI is proud to be in the forefront of technology to assist the medical community in the battle against Covid-19 and any future health crisis,” says Kaz Haruna, National Sales Manager for IAI America. The current pandemic creates an urgent need for readily available multiple testing and diagnostic tools worldwide.

IAI is actively assisting the medical community by providing Cartesian and SCARA robots for infectious disease testing, molecular diagnostics, tissue and blood sampling, genomic research, cancer research, pharmaceuticals, and medical device production. It is IAI’s hope that our ELECYLINDER Series will help the medical/pharmaceutical industries move ahead with advanced innovation.

About IAI: Founded in Shimizu, Japan in 1976, Intelligent Actuator Incorporated (IAI) has over forty years of experience in the design and manufacture of customized medical and industrial robotics. Built on “Quality and Innovation,” IAI is a leader in the research and development of advanced energy-efficient and affordable Cartesian, SCARA, and Tabletop robots. From entry-level to high-speed models, IAI provides complete programmable systems and components to fulfill any and all of your medical testing and industrial production needs.

IAI Map Location

 

 

 

 

 

 

★ USA Headquarters & Western Region
2690 West 237 Street, Torrance, CA 90505
(310) 891-6015

★ Midwest Branch Office
110 East State Parkway, Schaumburg, IL 60173
(847) 908-1400

★ Southern Branch Office
1220 Kennestone Circle, Suite 108
Marietta, GA 30066(678) 354-9470

★ Japan Headquarters
577-1 Obane, Shimizu-ward
Shizuoka-city, Shizuoka-pref.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.